|
|
 |
|
Viewing report
|
|
|
|
Oncology Pipelines: Is the Future Targeted Therapy?
Decision Resources, Inc, May 2007, Pages: 39
Drug companies’ cancer pipelines are bulging, and hundreds of new drugs are in development—the modern equivalent of a gold rush. Remarkable successes have been recorded with targeted oncology, but the treatment of more than 200 types of cancer remains a daunting task. Today’s three principal modalities of cancer treatment—surgery, radiotherapy, drug treatment—have begun to give way to new targeted techniques.
Genentech/Roche/Chugai’s Herceptin and ten other blockbuster “targeted” therapies have shown that drugs designed to interact with specific molecular targets can hit cancer where it hurts. However, targeted therapies are no panacea; to continue advancing cancer treatment, investigators must continue to improve their understanding of specific drug targets and continue to explore gene regulation and protein networks, to which targeted oncology therapies owe their existence.
Get the Answers You Need to Shape Your Strategy
- In 2007, there were 11 highly successful targeted cancer blockbusters. Which drugs were they, and which blockbusters also carried a strong warning label: namely, the dreaded “black box” authorized by the FDA?
- Amgen recently suffered several setbacks, including unfavourable trial results from a Phase III trial of Vectibix in first-line, metastatic colorectal cancer. But Amgen still has upward of 60 ongoing development programs. Why is this company still in need of a more vibrant pipeline?
- Bristol-Myers Squibb has a solid presence in targeted oncology drugs with its blockbuster drug Erbitux.
- Which other drug in Bristol-Myers Squibb’s portfolio represents a significant achievement in the rational design of drugs to overcome drug resistance in cancer?
- With Avastin, Herceptin, and Rituxan/MabThera, Genentech and Roche are on track to rack up more than $11 billion in combined worldwide revenues in 2007. Competition is on the way, however. Which companies have drugs in Phase III trials for non-small-cell lung cancer? What are Genentech/Roche’s strategies for expanding their prolific oncology franchise?
- For the last few years, ImClone has been sidetracked by legal issues; yet ImClone still claims a legitimate cancer blockbuster: Erbitux, the first targeted cancer therapy approved for colorectal cancer. Why have unfavorable results of Amgen’s Vectibix made clinicians, investigators, and investors anxious about Erbitux’s future potential?
- Much excitement accompanied the completion of sequencing the human genome, circa 2000. But the excitement soon gave rise to somber reflection: the sequencing itself did not immediately point the way to a bevy of new oncology drugs. What work still needs to be done for human genome sequencing to realize its promise of helping to provide personalized, targeted cancer therapies?
Scope
- Cancer therapy today and tomorrow: limitations of the three principal modalities of current cancer treatment; addressing unmet needs; targeted cancer therapy and personalized medicine; changes in the drug development paradigm.
- Leaders in oncology: the world’s best-selling oncology drugs and the key products in 11 leading oncology franchises.
- Oncology pipelines: Amgen’s woes; AstraZeneca’s disappointment; Bristol-Myers Squibb’s expansion; Exelixis’s aggressive discoveries; Genentech/Roche’s leading oncology franchise; Genmab’s waves; GlaxoSmithKline’s oncological advances; ImClone’s legitimate blockbuster; ImmunoGen’s “armed” technology; Novartis’s kinase inhibitors; Pfi zer’s bandwagon-jumping.
- Waves of the future: human genome sequencing; the oncology gold rush; RNA targeted therapies.
- Spectrum expert commentaries: two separate commentaries in which leading oncology experts explore the challenges, discoveries, and intricate mechanisms of personalized cancer treatment and the use of microRNA modulators.
|
|
|
|
